Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2025-05-15 Foreign Filer Report
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2025-05-15 English
Inside Information / Other news releases
Investor Presentation Classification · 1% confidence The document is a press release dated May 15, 2025, announcing that abstracts related to the company's drug candidates (IPH6501 and SAR'514/IPH6401) have been selected for presentation at the European Hematology Association (EHA) Congress 2025. This type of announcement, detailing scientific data presentation schedules and abstract codes, is characteristic of an Investor Presentation (IP) or a general corporate update, but it is not a full financial report (10-K, IR), a management discussion (MDA), or a formal earnings release (ER). Since it is a detailed announcement about scientific data being presented at a major industry conference, it aligns best with the 'Investor Presentation' category, as these announcements often precede or accompany investor briefings focused on scientific progress. It is not a simple announcement of a report publication (RPA) because it contains substantial scientific detail about the abstracts themselves, rather than just stating a report is available.
2025-05-15 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Innate Pharma announcing that abstracts related to their drug candidates (IPH6501 and SAR'514/IPH6401) have been selected for presentation at the EHA 2025 annual congress. It details the abstract codes, session times, and provides background information on the ANKET® platform and the company itself. This type of announcement, which communicates scientific data acceptance for a conference, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or an Earnings Release (ER) if it contained financial results. Since this is an announcement about scientific data being presented at a medical congress, and it is not a formal financial report (like 10-K or IR) or a general regulatory filing (RNS), it most closely aligns with the dissemination of information intended for investors regarding scientific progress. However, given the specific definitions, it is not a formal Investor Presentation (IP) which usually contains strategy/financials, nor is it an Earnings Release (ER). It is a specific announcement about scientific data presentation. In the context of the provided definitions, this type of scientific/clinical update announcement, which is not a formal financial report, often falls under a general regulatory announcement or a specific category if available. Since it is a press release announcing scientific progress (abstract selection), and not a formal financial report, it is best categorized as a general Regulatory Filing (RNS) as a catch-all for non-standard announcements, or potentially an Investor Presentation (IP) if the focus is heavily on future product potential. Given the content focuses on abstract selection for a medical congress, which is a key milestone for investors, 'IP' is plausible, but 'RNS' is the safest fallback for non-financial, non-standard corporate news releases. Upon review, these types of scientific updates are often grouped with Investor Presentations (IP) as they are key pieces of forward-looking information for investors, even if they aren't the full presentation deck. However, since it is a press release *announcing* the abstract selection, and not the presentation itself, it functions as a general corporate announcement. I will classify it as RNS as it is a specific corporate announcement that doesn't fit the core definitions of ER, IR, or IP (which usually implies the deck itself).
2025-05-15 French
6-K
Foreign Filer Report
2025-05-13 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces the company's activities and financial results for the first quarter of 2025 ("RÉSULTATS FINANCIERS POUR LE PREMIER TRIMESTRE 2025"). It provides key financial highlights (cash position, revenue) and operational updates (clinical trial progress, partnerships). This structure—a brief announcement summarizing key figures and operational milestones for a specific reporting period (Q1 2025)—is characteristic of an Earnings Release (ER). It is not the comprehensive quarterly report (IR) nor the full annual report (10-K). The document also mentions a conference call, which is typical for an ER. Q1 2025
2025-05-13 French
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is explicitly titled "INNATE PHARMA REPORTS FIRST QUARTER 2025 BUSINESS UPDATE AND FINANCIAL RESULTS" and contains key financial figures for the period ending March 31, 2025, including revenue and cash position. It also mentions a conference call scheduled for the same day. This structure—reporting period results, pipeline updates, and a call announcement—is characteristic of an Earnings Release (ER). While it contains comprehensive pipeline updates, the primary focus and framing are on the quarterly financial results announcement, making ER the most appropriate classification over a comprehensive Interim Report (IR) or a simple announcement (RPA/RNS), especially given the document length suggests it is the full release, not just a notification of release. Q1 2025
2025-05-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.